

1 NUTRITION REVIEWS

2
3
4 TITLE PAGE

5
6 **Article Type:** *Nutrition in Clinical Care*

7
8
9 **Title:** Effect of non-meat, high protein supplementation on quality of life and clinical
10 outcomes for older people living in care homes: systematic review and meta-analysis.

11
12
13 **Authors:** Alison I C Donaldson^{1,2}, Toby O Smith³, Sarah Alder², Alexandra M Johnstone⁴, Baukje
14 De Roos⁴, Lorna S Aucott⁵, Adam L Gordon⁶, Phyo K Myint^{1,2}

15
16
17 **Affiliations:**

18
19 ¹Ageing Clinical & Experimental Research (ACER) Team, Institute of Applied Health Sciences,
20 School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK

21
22 ²Academic Department of Medicine for the Elderly, Aberdeen Royal Infirmary, NHS Grampian,
23 Aberdeen, UK

24
25 ³Nuffield Department of Orthopaedic, Rheumatology and Musculoskeletal Sciences,
26 University of Oxford, Oxford, UK

27
28 ⁴Rowett Institute of Nutrition & Health, School of Medicine, Medical Sciences & Nutrition,
29 University of Aberdeen, Aberdeen, UK

30
31 ⁵Medical Statistics Group, Institute of Applied Health Sciences, School of Medicine, Medical
32 Sciences & Nutrition, University of Aberdeen, Aberdeen, UK

33
34 ⁶Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, UK

35
36
37 **Correspondence Address:**

38 Dr Toby Smith, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
39 Sciences, Botnar Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD.
40 Email: toby.smith@ndorms.ox.ac.uk

41
42 Dr Alison Donaldson, Ageing Clinical & Experimental Research (ACER) Team, Institute of
43 Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of
44 Aberdeen, Aberdeen, AB25 2ZD, UK. Email: alison.donaldson@abdn.ac.uk

47

48 **ABSTRACT**

49

50 **CONTEXT:** Care home residents are at risk of malnutrition through reduced overall food intake,
51 'anabolic resistance' in ageing muscle and high prevalence of medical morbidity and functional
52 dependency. There has been limited consensus regarding effectiveness of a high protein diet on
53 quality of life or clinical outcomes for care home residents.

54

55 **OBJECTIVE:** To evaluate the effectiveness of non-meat, high protein supplementation on Health-
56 Related Quality of Life (HRQOL) and relevant clinical and nutritional outcomes in older people in the
57 care home setting.

58

59 **DATA SOURCES:** We searched EMBASE, AMED, CINAHL, MEDLINE, and the Cochrane Registry of
60 Clinical Trials, OpenGrey, clinicaltrials.gov, the WHO clinical trial registry and the ISRCTN and NIHR trial
61 portfolio (to February 2018) for randomised controlled trials.

62

63 **DATA EXTRACTION:** We extracted data from included trials if they assessed people aged 65 years and
64 over living in care homes, who received a protein supplementation compared to not.

65

66 **DATA ANALYSIS:** We assessed trial quality using Cochrane Risk of Bias tool and meta-analysis was
67 undertaken when appropriate.

68

69 **RESULTS:** 17 papers with 1,246 participants fulfilled the inclusion criteria. All studies were low or
70 moderate quality. No evidence of improving HRQOL when the SF-36 was used (Standardised Mean
71 Difference (SMD: -0.10; 95% CI: -0.51 to 0.31; p=0.62), although significant improvement was seen in
72 the single trial using EQ-5D (SMD: 2.58; 95% CI: 2.05 to 3.10; p<0.00001).

73

74 **CONCLUSIONS:** Non-meat, high-protein oral supplements can improve markers of nutritional status in
75 care home residents. However, there is insufficient high-quality evidence to determine the effect of
76 such interventions for older adults in care homes with regard to HRQOL.

77

78 **SYSTEMATIC REVIEW REGISTRATION:** PROSPERO - Reg No: CRD42015029313.

79

80 **KEYWORDS:** High protein; care homes; older people; quality of life; appetite

81

82
83
84

INTRODUCTION

85 In the UK 425,000 individuals live in care homes for older people. These are long-term care
86 facilities which may, or may not, have specialist nursing input but which universally provide
87 care for people with multiple morbidities and advanced functional dependency and who can
88 no longer be supported in their own home.¹ The care home bed-base is about three times
89 that for acute hospitals and care outcomes for care home residents are increasingly
90 recognised to impact upon all of health and social care.² An important source of morbidity for
91 care home residents is malnutrition, defined as a state of nutrition in which a deficiency,
92 excess or imbalance of energy, protein and other nutrients causes measurable adverse effects
93 on tissue/body form, function and clinical outcome.³ This affects approximately 30% of older
94 people living in care homes with a particular risk of protein energy malnutrition.⁴ The
95 multitude of poor outcomes attributable to inadequate nutrition include: increased risk of
96 infections, dehydration, falls, inability to perform activities of daily living (ADLs) and reduced
97 health-related quality of life (HRQOL).⁵ While malnutrition does not have to be an
98 inevitability of ageing, there are several factors putting older adults at risk, including reduced
99 appetite, poor dentition, swallowing problems, altered taste and smell.⁵ All of these may be
100 addressed by high protein oral nutritional supplements (ONS), which may be of particular use
101 in care homes because the care home staff supervise both dietary intake and administration
102 of medicines/supplements.^{6,7}

103

104 The most commonly administered ONS are protein enriched drinks which are easy to
105 administer, require no mastication and are less satiating than solids.⁸ Supplementation of
106 dietary protein from a non-meat source avoids matters of cultural beliefs around food

107 choices, as several religions and cultures prohibit consumption of particular meats, and this
108 can be more sustainable from an environmental perspective.^{9,10} While animal sources of
109 protein deliver all the essential amino acids, the environmental impact from producing
110 livestock for meat is almost double that associated with supporting a lacto-ovo-vegetarian
111 diet.¹¹

112
113 While many older people are affected by multiple chronic diseases, most regard the presence
114 or absence of disease less important than their overall quality of life.¹² Numerous systematic
115 reviews have reported the prevalence of malnutrition among older adults. However, there is
116 little evidence from systematic reviews to establish the best nutritional support for older
117 adults in care homes.¹³ Older adults are at particular risk of protein energy malnutrition as a
118 result of reduced overall food intake and ‘anabolic resistance’ in ageing muscle.^{6,14}
119 Additionally, few papers have assessed the evidence regarding effectiveness of a high protein
120 diet on quality of life or clinical outcomes for care home residents.^{15,16} The primary purpose
121 of this study was to address this and to perform a systematic review to assess the effect of
122 supplementation on quality of life for older people living in care homes.

123 124 125 126 **METHODS**

127 128 *Protocol*

129 The protocol for the review was registered on PROSPERO (Reg No: CRD42015029313).

130 131 *Reporting*

132 This systematic review has been reported in accordance with the PRISMA guidelines (Table
133 S1).¹⁷
134
135

136 *Search Strategy*

137 A primary literature search was performed using the published literature databases: EMBASE,
138 AMED, CINAHL, MEDLINE, and the Cochrane Registry of Clinical Trials. In addition,
139 unpublished literature databases were also searched including OpenGrey, clinicaltrials.gov,
140 the WHO clinical trial registry and the ISRCTN and NIHR trial portfolio. We searched
141 databases from their inception to 1st February 2018. The MEDLINE search strategy is
142 presented in Table S2 and was modified for each database. We reviewed the reference lists of
143 eligible studies and contacted the corresponding authors from each included paper where
144 contact details were available, to identify any previously omitted trials. Three replies were
145 received out of 13 enquiries.

146

147 *Eligibility*

148 We included studies which were: randomised controlled trials involving a non-meat, high-
149 protein dietary intervention; for people who were aged 65 years or over; and conducted on
150 residents in care homes. We defined high protein supplements as including >20g of protein
151 and >20% total calorie value from protein. We also included moderate protein supplements if
152 containing >10g protein or >10% of total calorie value from protein. We excluded trials where
153 participants were recruited during acute hospital or rehabilitation unit admissions or
154 conducted in sheltered housing settings. We included papers irrespective of country of origin,
155 or language or age of publication. We included all comparison arms which may have been
156 controls assigned to a standard diet or a placebo product, however we excluded trials where
157 there were co-interventions combined with a dietary intervention e.g. dietary intervention
158 plus physical activity. Where trials presented data on multiple intervention arms e.g. dietary

159 intervention vs. dietary intervention and physical activity vs. physical activity alone, data from
160 the dietary intervention alone group were extracted.

161

162 *Study Identification*

163 Two reviewers (AICD, SA) independently screened all titles and abstracts against the above
164 pre-defined eligibility criteria. We obtained the full-text of each paper which met the eligibility
165 criteria and these were re-reviewed independently by the two reviewers (AICD, SA). We
166 included those which met the criteria in the final analysis. Where disagreements occurred for
167 paper eligibility, these were discussed between the two reviewers and adjudicated by two
168 senior reviewers (TOS, PKM).

169

170 *Outcomes and Data Extraction*

171 The primary outcome was health related quality of life (HRQOL), including Short Form-36 (SF-
172 36), EQ-5D, and Dementia Quality of Life Measure (DEMqoL). Secondary outcomes included:
173 adverse events (including admissions to hospital, gastrointestinal symptoms), falls, functional
174 assessments, body weight, body mass index (BMI), mid-upper arm circumference (MUAC) and
175 grip strength. Data were extracted by one reviewer (AICD) and verified by a second reviewer
176 (SA). Disagreement was resolved by discussion and review of the source paper and
177 adjudicated by one senior reviewer (TOS). Data extracted included: participant characteristics,
178 details of the dietary intervention, trial design features and the outcomes of interest.

179

180 For body weight, BMI and MUAC, we recorded the change in each value for each group, and
181 where this value was not presented in the data, an estimate was made using the difference in

182 mean values for these outcomes from before and after intervention with an estimated
183 standard deviation (SD) using a correlation coefficient of 0.5.¹⁸

185 *Quality Assessment*

186 We assessed the quality of all included studies using the Cochrane Risk of Bias tool.¹⁹ This
187 was performed independently by two reviewers (AICD, SA). Any disagreement in appraisal
188 score was satisfied through discussion and adjudicated by a third reviewer (TOS).

190 *Data Analysis*

191 All the studies were RCTs. Effect size of such trials depends on how the 'control' has been
192 defined. Study heterogeneity was assessed through examination of the data extraction table,
193 assessing between-study variability in respect to participant, recruitment, intervention and
194 any co-interventions. We conducted a narrative analysis (reporting the trends in results
195 (descriptive and statistical) rather than pooling the data into a meta-analysis) when there was
196 study heterogeneity or insufficient data (less than two dataset presenting mean and standard
197 deviation or event count data for a specific outcome) to pool results. We performed a meta-
198 analysis when there was low risk of study heterogeneity. We assessed statistical
199 heterogeneity using the inconsistency-value (I^2) and Chi^2 . Where I^2 was 30% or less and Chi^2
200 $p > 0.10$, we conducted a fixed-effects model analysis. When these were not met, we
201 performed a random-effects model. We evaluated all continuous outcomes of HRQOL,
202 functional assessment, body weight, BMI, MUAC and grip strength using mean difference
203 (MD) for individual papers and presented in forest plot or standardised mean difference
204 (SMD) when trials used different measurements to capture the same domain. We assessed
205 categorical outcomes such as adverse events and falls using a risk ratio (RR).

206

207 We presented all analyses with 95% confidence intervals (CI) and forest-plots. We performed
208 pre-defined sub-group analyses of study outcomes by duration of intervention (> or ≤ 12
209 weeks) and total protein content. We classified protein content as high (>20g protein),
210 moderate (10-20g protein) or low (<10g protein). We classified calorie content as high (>20%
211 calories from protein), moderate (10-20% calories from protein), or low (<10% calories from
212 protein). Follow-up intervals were up to two years post-randomisation. We planned to
213 present a funnel plot for the primary outcome analysed and/or any analysis where there was
214 a minimum of 10 datasets, to assess small sample size publication bias.¹⁹ We intended to
215 examine the clustering effect if the original papers reported the data accounted for clustering
216 within a care home. We conducted all analyses in collaboration for verification by two
217 reviewers (AICD, TOS) using Review Manager (RevMan).²⁰ For all analyses, a P≤0.05 was
218 deemed statistically significant.

219

220 We made an analysis of the weight of the evidence for each individual outcome using the
221 GRADE approach.^{21,22} Through this, we categorised the strength of evidence underpinning
222 each analysis as high, moderate, low or very low, with evidence graded based on study
223 design, study quality, consistency, directness of evidence, precision and reporting bias.^{21,22}

224

225 **RESULTS**

226

227 *Study Selection*

228 The results of the search strategy are illustrated in the PRISMA flow-chart (Figure S1). As this
229 illustrates, the searches identified 431 potentially relevant papers, of which 17 fulfilled the

230 inclusion criteria.^{6,23-38} Two of the included papers reported on the same trial but participants
231 were only counted once.^{26,35} On stratifying the trials by protein content of the intervention,
232 five fulfilled our criteria of high protein (>20g protein and >20% of total calories from
233 protein)^{6,26,27,33,35,37} and 12 fulfilled our criteria of moderate protein (>10g protein or >10%
234 calories from protein).^{23-25,28-32,34,36,38}

235

236 *Study Characteristics*

237 Study characteristics are summarised in Table 1. A total of 1246 participants were identified
238 from 16 trials, (range: 34 to 175 participants).^{23,32} This included 271 males and 934 females;
239 the gender of 41 participants was not documented in one trial.²⁹ The study mean ages ranged
240 from 78.7 to 89.6 years.^{30,34} The presence of dementia or cognitive impairment indicated by
241 Mini Mental State Examination (MMSE) score was described in 13 trials.^{23-32,35,36,38} In this
242 systematic review, MMSE score of nine or below indicated severe cognitive impairment, 10 to
243 18 moderate cognitive impairment, 19 to 23 mild cognitive impairment and 24 to 30 as
244 normal cognition.³⁹ In the included trials, mean baseline MMSE ranged from 18 to 26^{23,29} and
245 in three trials 100% of participants had a diagnosis of dementia.³⁰⁻³² There was no consistent
246 measure of frailty, but several trials provided information on the prevalence of chronic
247 illness,^{25,28,32,34,35,37,38} ranging from a mean of 1.8 to five comorbid diseases.^{25,28}

248

249 The standard diet for participants prior to intervention contained a mean of 1560 kcal and
250 56g of protein daily. Interventions were mainly liquid: 10 studies used a milk based
251 supplement,^{6,24-27,30,31,35-38} one used a soya drink,²⁸ three used an enriched diet or a choice of
252 supplement,³²⁻³⁴ one used high protein cookies,²³ and one used an amino acid supplement²⁹.

253 Intervention protein content ranging from 8g²⁹ to 40g³³ with total calories 32kcal²⁹ to
254 600kcal.^{26,33-36,21,28-31} The duration of intervention ranged from four weeks⁶ to nine months.³⁷
255 The comparison used in 10 trials was standard diet,^{6,23,24,26,27,30-33,35,36} while four trials used a
256 placebo non-calorie drink,^{25,30,37,38} one trial used a snack of unspecified content,²⁸ one trial
257 used a placebo maltodextrin tablet,²⁹ and one provided dietary advice.³⁴

258
259
260

261 *Risk of Bias*

262
263 A summary of the Risk of Bias quality assessment is presented in Figure S2 and GRADE
264 assessment of outcomes in Table 2. There was a strong risk of selection and performance bias
265 due to the lack of blinding of participants and/or personnel in 14 trials,^{6,23,25-28,30,31,33-38} and
266 unclear blinding in two further trials.^{24,30} A placebo supplement was employed in six
267 trials,^{25,28-30,37,38} and blinding of the outcome assessor was described in five trials.^{25,29,36-38} The
268 risk of reporting bias was largely unclear^{6,23-37} and risk of attrition bias was high with an
269 attrition rate >15% in seven trials^{30,33-38} and not described in three.^{6,23,24}

270

271 *Health Related Quality of Life*

272
273 HRQOL was assessed by SF-36 in two trials^{29,33} and the EQ-5D in one trial.³⁴ Heterogeneity
274 was too high to draw conclusions from meta-analysis of the three trials, although this can be
275 seen in Figure 1 for interest only. On subgroup analysis, there was no evidence of improving
276 HRQOL when the multi-dimensional assessment tool SF-36 was used (SMD: -0.10; 95% CI: -
277 0.51 to 0.31; p=0.62; 2 trials), although significant improvement was seen in the single trial
278 using EQ-5D for which the intervention was classed as moderate protein content (SMD: 2.58;

279 95% CI: 2.05 to 3.10; $p < 0.00001$; 1 trial). Due to the significant heterogeneity between the
280 trials ($I^2 = 96\%$) and based on the GRADE assessment, the evidence was graded low quality.

281

282 *Adverse events, deaths and falls*

283 Four trials reported data on death^{25,34,35,38} and eight reported data on adverse events.²⁴⁻
284 ^{27,30,36,38} There was no significant difference in the number of reported adverse events (RR:
285 1.11; 95% CI: 0.70 to 1.76; Figure 2) and deaths (RR: 0.53; 95% CI: 0.22 to 1.25; Figure S3).
286 There was no available data on the incidence of falls in any of the trials. Study heterogeneity
287 was not significant for analysis of adverse events ($I^2 = 20\%$) or deaths ($I^2 = 0\%$). Based on the
288 GRADE assessment, the evidence underpinning the assessment of adverse events, deaths and
289 falls was graded low quality.

290

291 *Functional Assessment*

292 Two trials reported data on functional outcomes using the Barthel Index^{33,35} and two assessed
293 this domain using an alternative ADL based score.^{24,30} Study heterogeneity was not significant
294 ($I^2 = 0\%$). There were no significant differences between the control and intervention groups
295 (SMD: -0.04; 95% CI: -0.29 to 0.22; $p = 0.57$; Figure S4) including when limiting to the high
296 protein studies^{33,35} (SMD: -0.11; 95% CI: -0.44 to 0.23; $p = 0.41$). Based on the GRADE
297 assessment, the evidence was graded low quality.

298

299 *Body Weight*

300 The mean change in mean body weight was reported in 13 trials.^{23-28,30,31,33-36,38} Meta-analysis
301 showed significant increase in mean body weight with intervention across all included trials

302 (MD: 1.11; 95% CI: 0.97 to 1.24; p<0.0001; Figure S5). This effect was also evident in the high
303 protein group ^{26,27,33} (MD: 2.12; 95% CI: 1.34 to 2.91; p<0.00001; Figure S5), and by a smaller
304 magnitude in the moderate protein group (MD: 1.08; 95% CI: 0.94 to 1.21; p<0.00001; Figure
305 S5).^{23-25,28,30,31,34-36,38} Based on the GRADE assessment, the evidence was graded moderate
306 quality with overall substantial study heterogeneity (I² = 75%).

307

308 *Body Mass Index*

309 The mean change in BMI was reported in eight trials.^{24,27,28,30,33,35-37} Meta-analysis showed
310 significant increase in mean BMI across all included trials (MD: 0.86; 95% CI: 0.61 to 1.10;
311 p<0.00001; Figure S6). This effect was seen in both the high protein group ^{27,33,37} (MD: 1.05;
312 95% CI: 0.68 to 1.41; p=0.0004; Figure S6) and in the moderate protein group ^{24,28,30,35,36}(MD:
313 0.70; 95% CI: 0.37 to 1.03; p<0.00001; Figure S6). The analyses on BMI were graded as
314 moderate quality evidence using the GRADE approach with low overall study heterogeneity (I²
315 = 0%).

316

317 *Mid-upper-arm Circumference (MUAC)*

318 The mean change in MUAC was reported in six trials.^{24,26,28,30,35,36} The MUAC was maintained
319 better in the intervention group than the control group (MD: 0.51; 95% CI: 0.23 to 0.79;
320 p=0.0004; Figure S7). The GRADE assessment for change in MUAC measures was moderate
321 quality with substantial overall study heterogeneity (I² = 73%).

322

323 *Grip Strength*

324 Grip strength was assessed in five trials.^{24,27,32,33,35} These demonstrated substantial statistical
325 heterogeneity ($I^2 = 60\%$). There was a significant change in grip strength in the 'moderate'
326 protein subgroup (MD: 1.29; 95% CI: 0.45 to 2.14; $p = 0.003$; Figure S8), and although the
327 change in the 'high protein' subgroup was not statistically significant, there does appear to be
328 a tendency of an effect (MD: 0.63; 95% CI: -0.05 to 1.32; $p = 0.07$; Figure S8). Based on the
329 GRADE assessment, the evidence was graded low quality.

330

331 *Duration of Interventions*

332 There were 12 trials (reported in 13 papers) with ≤ 12 week intervention duration^{6,23-27,29-35}
333 and four trials with intervention lasting > 12 weeks.^{28,36-38} Minimum length of intervention
334 was four weeks⁶ and longest duration of intervention was nine months.³⁷ Subgroup analysis
335 by duration of intervention ($>$ or ≤ 12 weeks) was not significant for adverse events ($p = 0.84$),
336 deaths ($p = 0.61$), change in body weight ($p = 0.12$) or change in BMI ($p = 0.16$). However, there
337 were significant subgroup differences for MUAC ($p = 0.005$) with stronger effect for > 12 weeks
338 of intervention (MD 0.95; 95% CI: 0.53 to 1.37; $p < 0.00001$) compared to ≤ 12 weeks (MD
339 0.14; 95% CI: -0.24 to 0.52; $p = 0.47$). There was insufficient data to examine the effect of
340 duration of intervention for grip strength.

341

342 **DISCUSSION**

343

344 The key finding of our systematic review is that whilst a non-meat, high protein enriched
345 dietary intervention appears to be effective for surrogate markers of clinical outcomes, there

346 is a paucity of high-quality evidence of the affect regarding HRQOL, an important health
347 outcome in old age.

348

349 Surprisingly, few trials objectively measured HRQOL. It was interesting to note that even
350 within the high protein subgroups, there was no evidence of improving HRQOL on a
351 multidimensional SF-36 assessment ($p=0.62$). Nonetheless the single trial which reported EQ-
352 5D demonstrated a significant improvement in HRQOL even at the moderate protein criteria
353 ($p<0.00001$).³⁴ Since this was only a single study which presented with a number of
354 methodological limitations, the evidence for EQ-5D remains limited, but does provide a signal
355 which should be further investigated. Notably, of those studies including HRQOL as an
356 outcome measure, inclusion of participants with a diagnosis of dementia was lacking. This
357 absence of data on the effect of high protein diet on HRQOL in care homes for those with
358 cognitive impairment or dementia must be addressed in future research given that this group
359 comprises a significant proportion of care home residents. Perhaps this paucity of data
360 reflects the difficulties in assessing self-reported measures like HRQOL in populations with a
361 high prevalence of dementia using validated tools without relying on a proxy. Even in
362 relatively simple HRQOL measures with validated proxy versions, most notably, the EQ-5D,
363 there are acknowledged issues with relying on proxy respondents in the care home setting.⁴⁰
364 However, dementia-specific HRQOL measures, such as the DEMQoL, should be considered for
365 future studies.⁴¹

366

367 Only four trials incorporated an objective measure of change in function ^{24,29,33,35} (Barthel
368 Index or ADL score) and it is possible that the time frame of the included trials was too short
369 to show any significant variation. Similarly, whilst there was a tendency for a difference, the

370 study interventions did not significantly differ by grip strength ($p=0.07$). However grip
371 strength measures have previously been noted to be very low among care home residents⁴²
372 and may be affected by both a floor effect and poor sensitivity to change. It could be that the
373 relatively invasive nature of the investigations to measure such outcomes, such as muscle
374 biopsy and DEXA scanning, in cohorts of older, frailer individuals has proved off-putting for
375 researchers working in the care home setting. More recent innovations in measuring muscle
376 turnover, including microbiopsy, ultrasonographic and excreted amino-acid derived indices of
377 muscle turnover could potentially allow more sensitive outcome measures to be employed in
378 this very frail cohort.⁴³

379

380 While no significant change in adverse effects or deaths were noted among participants
381 receiving a protein-rich nutritional intervention, a previous meta-analysis of protein and
382 energy supplementation in older people reported that there was a reduction in the mortality
383 rate for those malnourished at baseline.^{15,44} In the trials included in this review, generally
384 only those in the 'normal' BMI range were randomised, and therefore changes may have
385 been apparent if the low BMI, and therefore likely more malnourished group were also
386 included.

387

388 It is important to consider that the population represented in the studies may have been a
389 sub-cohort of the care home population, rather than representative of the population as a
390 whole. Certainly the reported co-morbidities in those trials which described this, were
391 significantly lower than in most cohort studies of care home residents, suggesting that this
392 may have been a less comorbid and less frail sub-population. Of note, those studies which
393 were conducted in groups without dementia were almost certainly a subset, given that the

394 estimated prevalence of dementia in cohort studies of care home residents is between 69%
395 and 80%.^{45,46}

396
397 Meta-analysis found small but statistically significant gains in both body weight (MD: 1.11kg)
398 and BMI (MD: 0.86 kg/m²), with a more significant effect noted in the higher protein group on
399 sub-analysis (MD: 2.12kg). Likewise, other meta-analyses also found significant increases in
400 body weight following protein supplementation in older adults.^{44,47} However, we recognise
401 an increase in skeletal muscle mass specifically, rather than body weight, would be the
402 desired outcome for improved function and HRQOL. While a meta-analysis by Dewansingh et
403 al showed a tendency to increase lean body mass from supplementing with >20g of protein
404 per day, a trial of long-term leucine supplementation in healthy older men did not improve
405 skeletal muscle mass or strength.^{47,48} Lean body mass is an important surrogate marker of
406 nutritional status, which should be included in future studies, this was omitted from this
407 meta-analysis as there were no results available for any of the studies.

408
409 It has been previously suggested that nutritional status can be improved by protein
410 supplementation.^{44,49,50,11,38,39} Our review supports that the macronutrient composition of
411 nutritional supplements, in terms of the protein content, may have a direct influence on the
412 extent of nutritional gains derived by older adults in residential care. Similarly, a study of
413 protein intake for more than 2,000 elderly participants demonstrated that those in the
414 highest quintile of protein intake lost significantly less lean body mass over three years than
415 those in the lowest quintile.⁵¹ This is particularly interesting given that protein rich diets have
416 gained huge popularity as a weight loss strategy, in part relying on the satiating effect of
417 protein to prevent excess calorie ingestion.⁵²

418

419 The strengths of this study relate to the systematic way in which we have approached the
420 literature. The main limitations relate to the narrow focus of our question, with focus on non-
421 meat protein supplementation and HRQoL related outcomes in a care home setting. The
422 paucity of data in this arena, whilst an important catalyst to further research, should not be
423 seen as representative of the broader literature on nutrition and patient outcomes.

424

425

426 **CONCLUSION**

427 High-protein oral supplements can improve markers of nutritional status (body weight and
428 BMI) in care home residents, but there is insufficient high-quality evidence to determine the
429 effect of non-meat, high protein interventions for older adults in residential care with regard
430 to HRQOL.

431

432 **DECLARATIONS**

433

434 **Acknowledgements:** We gratefully acknowledge the comments and suggestions by Dr Miles
435 Witham, Reader in Ageing and Health, University of Dundee and Professor Alison Avenell,
436 Professor of Health Services Research, University of Aberdeen.

437

438 **Statement of Authorship:** AICD, PKM, AMJ and BDR conceived the study. AICD & SA performed
439 screening, selecting and extraction of data. AICD and SA also performed quality assessment.
440 AICD and TOS conducted analyses and AICD drafted the manuscript. All co-authors
441 contributed to the writing of the paper.

442

443 **Conflict of Interest Statement:** No author declared a conflict of interest in relation to this
444 paper.

445

446 **Funding Sources:** No authors received funding in relation to the conduct or presentation of
447 this work. Dr Toby Smith is supported by funding from the National Institute for Health
448 Research (NIHR) Oxford Health Biomedical Research Centre.

449

450 **Ethical Approval:** No ethical approval was required to conduct or present this work.

451

452 **Data Availability:** We are able to provide the data which formed the basis of this analysis, on
453 request.

454 **Disclaimer:** The abstract was presented as an oral presentation at the BGS Spring meeting
455 2017 and will be published in the forthcoming supplementary issue of Age and Ageing.

456
457

458

459 **FIGURE AND TABLE LEGENDS**

460

461 **Figure 1:** Forest plot to assess quality of life assessments between the interventions on meta-
462 analysis

463 **Figure 2:** Forest plot to assess the adverse events reported between the interventions on
464 meta-analysis

465

466 **Table 1:** Summary of the characteristics of the included studies

467 **Table 2:** GRADE assessment of outcomes

468

469 **SUPPORTING INFORMATION**

470

471 **Table S1:** PRISMA Checklist

472 **Table S2:** Search strategy for MEDLINE

473

474 **Figure S1:** PRISMA flow diagram summarising the results of the search strategy

475 **Figure S2:** Results of the Risk of Bias assessment

476 **Figure S3:** Forest plot to compare the assessment of mortality between the interventions on
477 meta-analysis.

478 **Figure S4:** Forest plot to assess the functional assessment scores between the intervention
479 groups, on meta-analysis.

480 **Figure S5:** Forest plot to assess the change in mean body weight on meta-analysis

481 **Figure S6:** Forest plot to assess the change in mean body mass index on meta-analysis

482 **Figure S7:** Forest plot to assess the change in mean mid-upper-arm circumference (MUAC) on
483 meta-analysis

484 **Figure S8:** Forest plot to assess the outcome of grip strength measurement on meta-analysis.

485 **REFERENCES**

486

487 (1) Gordon AL, Franklin M, Bradshaw L, Logan P, Elliott R, Gladman JR. Health status of UK
488 care home residents: a cohort study. *Age Ageing* 2014;43:97-103.

489 (2) NHS England. New care models - The framework for enhanced health in care homes. 2016;
490 Available at: [https://www.england.nhs.uk/wp-content/uploads/2016/09/ehch-framework-](https://www.england.nhs.uk/wp-content/uploads/2016/09/ehch-framework-v2.pdf)
491 [v2.pdf](https://www.england.nhs.uk/wp-content/uploads/2016/09/ehch-framework-v2.pdf). Accessed 18th May, 2018.

492 (3) British Association for Parenteral and Enteral Nutrition (BAPEN). Introduction to
493 Malnutrition. 2018; Available at: [http://www.bapen.org.uk/malnutrition-](http://www.bapen.org.uk/malnutrition-undernutrition/introduction-to-malnutrition)
494 [undernutrition/introduction-to-malnutrition](http://www.bapen.org.uk/malnutrition-undernutrition/introduction-to-malnutrition). Accessed 18th May, 2018.

495 (4) Suominen M, Muurinen S, Routasalo P, Soini H, Suur-Uski I, Peiponen A, et al. Malnutrition
496 and associated factors among aged residents in all nursing homes in Helsinki. *Eur J Clin Nutr*
497 2005;59:578-583.

498 (5) The Caroline Walker Trust. Eating well for older people (Second Edition). Second ed.
499 London: The Caroline Walker Trust; 2004.

500 (6) Iuliano S, Woods J, Robbins J. Consuming two additional serves of dairy food a day
501 significantly improves energy and nutrient intakes in ambulatory aged care residents: a
502 feasibility study. *J Nutr Health Aging* 2013;17:509-513.

503 (7) Landi F, Calvani R, Tosato M, Martone AM, Ortolani E, Saveria G, et al. Protein Intake and
504 Muscle Health in Old Age: From Biological Plausibility to Clinical Evidence. *Nutrients*
505 2016;8:10.3390/nu8050295.

506 (8) Nieuwenhuizen WF, Weenen H, Rigby P, Hetherington MM. Older adults and patients in
507 need of nutritional support: review of current treatment options and factors influencing
508 nutritional intake. *Clin Nutr* 2010;29:160-169.

509 (9) van der Zanden LD, van Kleef E, de Wijk RA, van Trijp HC. Knowledge, perceptions and
510 preferences of elderly regarding protein-enriched functional food. *Appetite* 2014;80:16-22.

511 (10) Appleton KM. Barriers to and Facilitators of the Consumption of Animal-Based Protein-
512 Rich Foods in Older Adults. *Nutrients* 2016;8:187.

513 (11) Pimentel D, Pimentel M. Sustainability of meat-based and plant-based diets and the
514 environment. *Am J Clin Nutr* 2003;78(3 Suppl):660S-663S.

515 (12) Amarantos E, Martinez A, Dwyer J. Nutrition and quality of life in older adults. *J Gerontol*
516 *A Biol Sci Med Sci* 2001;56 Spec No 2:54-64.

517 (13) Gordon AL, Logan PA, Jones RG, Forrester-Paton C, Mamo JP, Gladman JR, et al. A
518 systematic mapping review of randomized controlled trials (RCTs) in care homes. *BMC Geriatr*
519 2012;12:31-2318-12-31.

520 (14) Landi F, Calvani R, Tosato M, Martone AM, Ortolani E, Saveria G, et al. Protein Intake and
521 Muscle Health in Old Age: From Biological Plausibility to Clinical Evidence. *Nutrients*
522 2016;8:10.3390/nu8050295.

523 (15) Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older
524 people. *Ann Intern Med* 2006;144:37-48.

525 (16) Elia M, Stratton R. On the ESPEN guidelines for nutritional screening 2002. *Clin Nutr*
526 2004;23:131-132.

527 (17) Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for
528 systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62:1006-
529 1012.

530 (18) Cochrane Handbook for Systematic Reviews of Interventions. Imputing standard
531 deviations. 2011; Available at:
532 http://handbook.cochrane.org/chapter_16/16_1_3_1imputing_standard_deviations.htm.
533 Accessed Jan, 2017.

534 (19) The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of
535 Interventions. 2011; Available at: <http://handbook.cochrane.org/>. Accessed June, 2016.

536 (20) The Cochrane Collaboration C. Review Manager (RevMan) Version 5.3. 2014;5.3.

537 (21) Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of
538 evidence and strength of recommendations. *BMJ* 2004;328:1490.

539 (22) Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an
540 emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*
541 2008;336:924-926.

542 (23) Pouyssegur V, Brocker P, Schneider SM, Philip JL, Barat P, Reichert E, et al. An innovative
543 solid oral nutritional supplement to fight weight loss and anorexia: open, randomised
544 controlled trial of efficacy in institutionalised, malnourished older adults. *Age Ageing*
545 2015;44:245-251.

546 (24) Kwok T, Woo J, Kwan M. Does low lactose milk powder improve the nutritional intake
547 and nutritional status of frail older Chinese people living in nursing homes? *J Nutr Health*
548 *Aging* 2001;5:17-21.

549 (25) Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, et al. Exercise
550 training and nutritional supplementation for physical frailty in very elderly people. *N Engl J*
551 *Med* 1994;330:1769-1775.

552 (26) Jobse I, Liao Y, Bartram M, Delantonio K, Uter W, Stehle P, et al. Compliance of nursing
553 home residents with a nutrient- and energy-dense oral nutritional supplement determines
554 effects on nutritional status. *J Nutr Health Aging* 2015;19:356-364.

555 (27) Lauque S, Arnaud-Battandier F, Mansourian R, Guigoz Y, Paintin M, Nourhashemi F, et al.
556 Protein-energy oral supplementation in malnourished nursing-home residents. A controlled
557 trial. *Age Ageing* 2000;29:51-56.

558 (28) Lee LC, Tsai AC, Wang JY, Hurng BS, Hsu HC, Tsai HJ. Need-based intervention is an
559 effective strategy for improving the nutritional status of older people living in a nursing home:
560 a randomized controlled trial. *Int J Nurs Stud* 2013;50:1580-1588.

561 (29) Rondanelli M, Opizzi A, Antonello N, Boschi F, Iadarola P, Pasini E, et al. Effect of
562 essential amino acid supplementation on quality of life, amino acid profile and strength in
563 institutionalized elderly patients. *Clin Nutr* 2011;30:571-577.

564 (30) Wouters-Wesseling W, Wouters AE, Kleijer CN, Bindels JG, de Groot CP, van Staveren
565 WA. Study of the effect of a liquid nutrition supplement on the nutritional status of psycho-
566 geriatric nursing home patients. *Eur J Clin Nutr* 2002;56:245-251.

567 (31) Wouters-Wesseling W, Slump E, Kleijer CN, de Groot LC, van Staveren WA. Early
568 nutritional supplementation immediately after diagnosis of infectious disease improves body
569 weight in psychogeriatric nursing home residents. *Aging Clin Exp Res* 2006;18:70-74.

570 (32) Young KW, Greenwood CE, van Reekum R, Binns MA. Providing nutrition supplements to
571 institutionalized seniors with probable Alzheimer's disease is least beneficial to those with low
572 body weight status. *J Am Geriatr Soc* 2004;52:1305-1312.

573 (33) Smoliner C, Norman K, Scheufele R, Hartig W, Pirlich M, Lochs H. Effects of food
574 fortification on nutritional and functional status in frail elderly nursing home residents at risk
575 of malnutrition. *Nutrition* 2008;24:1139-1144.

576 (34) Parsons EL, Stratton RJ, Cawood AL, Smith TR, Elia M. Oral nutritional supplements in a
577 randomised trial are more effective than dietary advice at improving quality of life in
578 malnourished care home residents. *Clin Nutr* 2017;36:134-142.

579 (35) Stange I, Bartram M, Liao Y, Poeschl K, Kolpatzik S, Uter W, et al. Effects of a low-volume,
580 nutrient- and energy-dense oral nutritional supplement on nutritional and functional status: a
581 randomized, controlled trial in nursing home residents. *J Am Med Dir Assoc* 2013;14:628.e1-
582 628.e8.

583 (36) Stow R, Ives N, Smith C, Rick C, Rushton A. A cluster randomised feasibility trial evaluating
584 nutritional interventions in the treatment of malnutrition in care home adult residents. *Trials*
585 2015;16:433-015-0952-2.

586 (37) Bonnefoy M, Cornu C, Normand S, Boutitie F, Bugnard F, Rahmani A, et al. The effects of
587 exercise and protein-energy supplements on body composition and muscle function in frail
588 elderly individuals: a long-term controlled randomised study. *Br J Nutr* 2003;89:731-739.

589 (38) Manders M, de Groot CP, Blauw YH, Dhonukshe-Rutten RA, van Hoeckel-Prust L, Bindels
590 JG, et al. Effect of a nutrient-enriched drink on dietary intake and nutritional status in
591 institutionalised elderly. *Eur J Clin Nutr* 2009;63:1241-1250.

592 (39) Mungas D. In-office mental status testing: a practical guide. *Geriatrics* 1991;46:54-8, 63,
593 66.

594 (40) Kane RL, Kane RA, Bershadsky B, Degenholtz H, Kling K, Totten A, et al. Proxy sources for
595 information on nursing home residents' quality of life. *J Gerontol B Psychol Sci Soc Sci*
596 2005;60:S318-S325.

597 (41) Smith SC, Lamping DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. Development of a
598 new measure of health-related quality of life for people with dementia: DEMQOL. *Psychol*
599 *Med* 2007;37:737-746.

600 (42) Roberts HC, Syddall HE, Sparkes J, Ritchie J, Butchart J, Kerr A, et al. Grip strength and its
601 determinants among older people in different healthcare settings. *Age Ageing* 2014;43:241-
602 246.

603 (43) Mitchell WK, Phillips BE, Williams JP, Rankin D, Lund JN, Wilkinson DJ, et al. The impact of
604 delivery profile of essential amino acids upon skeletal muscle protein synthesis in older men:
605 clinical efficacy of pulse vs. bolus supply. *Am J Physiol Endocrinol Metab* 2015;309:E450-7.

606 (44) Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly
607 people at risk from malnutrition. *Cochrane Database Syst Rev* 2009 Apr 15;(2):CD003288.
608 doi(2):CD003288.

609 (45) Matthews FE, Bennett H, Wittenberg R, Jagger C, Denning T, Brayne C, et al. Who Lives
610 Where and does it matter? Changes in the health profiles of older people living in long term
611 care and the community over two decades in a high income country. PLoS One
612 2016;11:e0161705.

613 (46) Alzheimer's Society. Dementia 2014 Report Statistics. 2014; Available at:
614 <https://www.alzheimers.org.uk/statistics>. Accessed October, 2016.

615 (47) Dewansingh P, Melse-Boonstra A, Krijnen WP, van der Schans CP, Jager-Wittenaar H, van
616 den Heuvel EGHM. Supplemental protein from dairy products increases body weight and
617 vitamin D improves physical performance in older adults: a systematic review and meta-
618 analysis. Nutr Res 2018;49:1-22.

619 (48) Verhoeven S, Vanschoonbeek K, Verdijk LB, Koopman R, Wodzig WK, Dendale P, et al.
620 Long-term leucine supplementation does not increase muscle mass or strength in healthy
621 elderly men. Am J Clin Nutr 2009;89:1468-1475.

622 (49) Cawood AL, Elia M, Stratton RJ. Systematic review and meta-analysis of the effects of
623 high protein oral nutritional supplements. Ageing Res Rev 2012;11:278-296.

624 (50) Elia M, Stratton R. On the ESPEN guidelines for nutritional screening 2002. Clin Nutr
625 2004;23:131-132.

626 (51) Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al. Dietary protein
627 intake is associated with lean mass change in older, community-dwelling adults: the Health,
628 Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr 2008;87:150-155.

629 (52) Johnstone AM. Safety and efficacy of high-protein diets for weight loss. Proc Nutr Soc
630 2012;71:339-349.

631

632


633

634

635

636

Figure 1: Forest plot to assess quality of life assessments between the interventions on meta-analysis



Footnotes
 (1) <20g or <20% protein. SF-36 score estimated from graph.
 (2) >20g and >20% protein
 (3) <20g or <20% protein.


637

638

639

640
641
642
643

Figure 2: Forest plot to assess the adverse events reported between the interventions on meta-analysis



644
645
646

Table 1: Summary of the characteristics of the included studies

Study	Country/ Setting	Number (control/ intervention)	Mean Age	Percentage female (%)	Baseline cognition	Mean baseline BMI	Baseline Diet	Dietary Intervention	Intervention protein content (g)	Intervention energy content (Kcal)	Placebo	Duration of intervention and follow-up
Smoliner et al ³³	Germany/ Nursing homes	52 (30/22)	85.2	73%	Not specified	CG: 22.5+3.4 IG: 21.6+3.6	2000kcal 80g protein	Enriched diet (using cream/oil) plus 300ml snacks	40 (from snacks alone)	600 (from snacks alone)	No	12 weeks
Bonnefoy et al ³⁷	France / Retirement home	57 (27/30)	83.0	88%	0% dementia (excluded)	CG: 27.32+0.8 IG: 27.13+0.9	2000kcal	400ml supplement drink	30	400	400ml non- calorie/ protein drink	9 months
Iuliano et al ⁶	Australia/ Low level care home	130 (62/68)	86.5	78%	Not specified	CG: 25.4+4.9 IG: 23.7+5.0	1497+-307kcal 56+-15g protein	2 servings of dairy foods (liquid/solid)	25+-12	215+-299	No	4 weeks
Josbe et al ²⁶ ; Stange et al ³⁵	Germany/ Nursing homes	87 (42/45)	87.0	91%	CG: 66% dementia IG: 80% dementia	CG: 22.5+3.1 IG: 23.0+3.4	1263+-374 kcal 41.3+-15.1g protein	250ml Fortimel Compact	24 (note one study reported as 48 but same intervention)	600	No	12 weeks
Lauque et al ²⁷	France/ Nursing homes	35 in comparable groups of same BMI status (22/13)	85.4 (estimated)	84%	CG: 68% dementia IG: 86% dementia	CG: 21.8+0.9 IG: 22.3+0.7	1573kcal 60g protein	300-400ml nutritional supplement drink	24	393+-23	No	60 days
Stow et al ³⁶	UK/ Care and nursing homes	93 (32/32+29)	Not described	82%	CG: 78% dementia IG(A): 78% dementia IG(B): 69% dementia	CG: 19 (17-20.5) IG(A): 20.1 (18.7-24.8) IG(B): 18.4 (17.6-21.6)	1553kcal 41g protein	A) 250-400ml food based liquid supplement B) 250-400ml liquid nutritional supplement	A) 20-25 B) 24	A) 600 B) 600	No	6 months
Kwok et al ²⁴	Hong Kong/ Nursing home	51 (24/28)	CG: 79.7 IG: 81.2	60%	CG: 9% dementia IG: 32% dementia	CG: 20.1+3.1 IG: 19.1+3.1	1198+-403kcal 61.6+-21.2g protein	2 cups of low-lactose milk	18.8	175	No	7 weeks

Parsons et al ³⁴	UK/ Care home	104 (51/53)	CG: 87.3 IG: 89.6	86%	0% dementia (excluded)	39% BMI <18.5 41% BMI 18.5-20	1360kcal 51.8g protein	Voluntary intake of range of supplements	Target 16	Target 600	Dietary advice	12 weeks
Fiatarone et al ²⁵	USA/ Care home	50 (26/24)	CG: 89.2 IG: 85.7	62%	Mean MMSE CG: 22.2+1 IG: 22.7+1.3	CG: 25.8+0.5 IG: 25.4+0.7	1485+-58kcal	240ml Supplement drink	15.3	360	240ml no calorie /protein drink	10 weeks
Pouyssegur et al ²³	France/ Nursing home	175 (87/88)	CG: 86.8 IG: 85.4	80%	Mean MMSE 18+-8.3	19.2+-2.9	Not specified	8 high protein cookies	11.5	244	No	6 weeks with 18 weeks follow-up
Young et al ³²	Canada/ Care home	34 (34/34) Crossover study	88.2	79%	100% dementia	23.8+-3.6	1514kcal 54.7+-17.4g protein	Various – mainly 75% of a supplement bar and a glass of juice	10.6	250	No	12 weeks
Wouters- Wess et al ³⁰	The Netherlands/ Psychogeriatric nursing home	34 (16/18)	82.7	85%	100% dementia	24.5+-4.2	1543+-377kcal 53.7+-18.3g protein	200ml supplement drink	11.2	300	No	5 weeks
Lee et al ²⁸	Taiwan/ Nursing home	92 (45/47)	CG: 80.2 IG: 78.9	58%	Mean MMSE CG: 14.1+-6.1 IG: 15.0+-5.5	CG: 20.31+-2.61 IG: 20.43+-2.50	Not specified	50g soy-protein based drink	9.5	250	Afternoon snack (content not specified)	24 weeks
Wouter- Wess et al ³¹	The Netherlands/ Psychogeriatric nursing home	35 (16/19)	CG: 78.7 IG: 85.3	89%	100% dementia	CG: 20.7+-2.7 IG: 20.7+-3.2	1496+-415kcal 55+-16g	250ml supplement drink	8.5	273	250ml non- calorie, no protein drink	3 months
Manders et al ³⁸	The Netherlands/ Care and nursing homes	176 (57/119)	CG: 81.0 IG: 81.0	74%	Mean MMSE CG: 24.0 (11.2-27.8) IG: 23.0 (9.6-27.4)	CG: 25.0+-3.5 IG: 26.1+-3.7	1793+-332kcal 58.8+-15.4g protein	250ml nutrient drink	8.75	250	250ml non- calorie, no protein drink	24 weeks
Rondanelli et al ²⁹	Italy/ Nursing home	41 (21/20)	CG: 79.9 IG: 83.5	Not specified	Mean MMSE CG: 21.1+-2.04 IG: 26.05+-2.09	CG: 22.1+-2.6 IG: 21.8+-2.3	59+-8g protein	8g Essential amino acid supplement	8	32	Maltodextrin tablet	8 weeks


Abbreviations: CG (control group); IG (intervention group); MMSE (mini mental state exam); BMI (Body mass index)

Table 2: GRADE Assessment of Outcomes

Outcome Measure	Quality Assessment				Number of Participants		Effect			EVIDENCE GRADE
	Design	Quality	Consistency	Directness	High protein intervention	Standard diet/ Placebo	MD/ SMD / RR (CI)	P value	I ²	
QOL (SF-36)	RCT	Low	Low	Moderate	42	51	SMD -0.10 (-0.51-0.31)	0.62	0%	LOW
QOL (EQ-5D)	RCT	Low	Low	Moderate	53	51	SMD 2.58 (2.05-3.10)	<0.00001	N/A	LOW
Adverse effects (group total)	RCT	Low	Low	High	335	268	RR 1.11 (0.70-1.76)	0.67	20%	LOW
Adverse effects (>20%/>20g protein)	RCT	Low	Low	High	82	83	RR 1.28 (0.64-2.55)	0.48	62%	LOW
Deaths (group total)	RCT	Moderate	Moderate	High	167	140	RR 0.53 (0.22-1.25)	0.15	0%	LOW
Deaths (>20%/>20g protein)	RCT	Moderate	Moderate	High	45	42	RR 0.40 (0.11-1.45)	0.16	N/A	LOW
Functional assessment (group total)	RCT	Low	Low	High	115	117	SMD -0.04 (-0.29-0.22)	0.79	0%	LOW
Functional assessment (>20%/>20g protein)	RCT	Low	Low	High	67	72	SMD -0.11 (-0.44-0.23)	0.53	0%	LOW
Change in mean body weight (group total)	RCT	High	High	High	446	440	MD 1.11 (0.97-1.24-)	<0.00001	75%	MODERATE
Change in mean body weight (>20%/>20g protein)	RCT	High	Moderate	High	50	87	MD 2.12 (1.34-2.91)	<0.00001	81%	MODERATE
Change in mean BMI (group total)	RCT	High	High	High	242	228	MD 0.86 (0.61-1.10)	<0.00001	0%	HIGH
Change in mean BMI (>20%/>20g protein)	RCT	High	High	High	65	79	MD 1.05 (0.68-1.41)	0.0004	0%	HIGH
Change in mean MAC (group total)	RCT	Moderate	Low	High	163	172	MD 0.51 (0.23-0.79)	0.0004	73%	LOW
Change in mean MAC (>20%/>20g protein)	RCT	Moderate	Low	High	57	70	MD 0.64 (0.11-1.18)	0.02	83%	LOW
Grip strength (group total)	RCT	Low	Low	High	122	128	MD 0.63 (-0.05-1.32)	0.07	60%	LOW
Grip strength	RCT	Low	Low	High	77	87	MD -0.63 (-1.80-0.53)	0.29	33%	LOW

>20%/>20g protein										
-------------------	--	--	--	--	--	--	--	--	--	--

Figure S1: PRISMA flow diagram summarising the results of the search strategy



**Reasons for exclusion:
trial not based on high protein intervention, trial not based in care home setting, trial involving exercise with no nutrition only group for comparison*

Figure S2: Results of the Risk of Bias assessment

Bonnetoy, 2003 [37]	+	+	+	?	-	-	
Fiatarone, 1994 [25]	+	+	+	?	?	-	
Iuliano, 2013 [6]	?	-	-	-	?	-	
Josbe, 2015 [26]	+	-	-	?	+	?	
Kwok, 2001 [24]	-	-	-	?	?	?	
Laque, 2000 [27]	?	-	-	?	+	+	
Lee, 2013 [28]	?	-	-	+	?	+	
Manders, 2009 [38]	-	+	+	?	-	?	
Parsons, 2016 [34]	+	-	-	-	?	-	
Pouyssegur, 2015 [23]	?	-	-	+	?	-	
Rondanelli, 2011 [29]	+	+	+	+	?	-	
Smoliner, 2008 [33]	?	-	-	?	?	-	
Stange, 2013 [35]	+	-	-	?	?	-	
Stow 1 (Food based) [36]	+	+	-	-	?	-	
Stow 2 (Oral Supp) [36]	+	+	-	-	?	-	
Wouters-Wess, 2002 [30]	?	?	+	?	?	?	
Wouters-Wess, 2005 [31]	?	-	-	-	?	?	
Young, 2004 [32]	+	?	-	?	+	-	
	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias

Figure S3: Forest plot to compare the assessment of mortality between the interventions on meta-analysis.




Figure S4: Forest plot to assess the functional assessment scores between the intervention groups, on meta-analysis.




Figure S5: Forest plot to assess the change in mean body weight on meta-analysis





Figure S6: Forest plot to assess the change in mean body mass index on meta-analysis



Footnotes

- (1) Estimated SD using within subject correlation coefficient of 0.5
- (2) Estimated SD using within subject correlation coefficient of 0.5
- (3) Estimated SD using within subject correlation coefficient of 0.5
- (4) Estimated SD using within subject correlation coefficient of 0.5
- (5) Estimated SD using within subject correlation coefficient of 0.5

Figure S7: Forest plot to assess the change in mean mid-upper-arm circumference (MUAC) on meta-analysis




Figure S8: Forest plot to assess the outcome of grip strength measurement on meta-analysis




Table S1: PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	TITLE PAGE
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	ABSTRACT
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	INTRO Para 3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	INTRO Para 3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Methods, Protocol
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Methods, Eligibility
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Methods, Search Strategy
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Methods, Study Identification

Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Methods, Outcomes and Data Extraction
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Methods, Outcomes and Data Extraction
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Methods, Quality Assessment
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Methods, Data Analysis
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Methods, Data Analysis, Para 1

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Methods, Data Analysis, Para 3
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Methods, Data

			Analysis, Para 2
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Supplement Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Results, Figure 1,2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Results, Figure 1,2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Results, section throughout
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Results, section throughout
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	Discussion, Para 1
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	Discussion, Para 5
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Discussion Para 2-4

FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Declarations

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Table S2: Search strategy for MEDLINE

PICOS Component	Search Strategy
Population	None Applied
Intervention	<ol style="list-style-type: none"> 1. Nutrit* 2. exp Nutrition Therapy/ 3. exp Diet/ 4. exp Diet Therapy/ 5. exp Eating/ 6. Oral nutritional supplement.ti.ab. 7. exp Dietary Supplements/ 8. exp Nutritional Support/ 9. Suppl*.ti.ab. 10. exp Dietary Proteins/ 11. (protein*) AND (feed* OR nutrit*)
Comparison	None Applied
Outcome	None Applied
Setting Design	<ol style="list-style-type: none"> 12. Care home*.ti.ab. 13. Old age home*.ti.ab. 14. Exp Homes for the Aged/ 15. Nursing home.ti.ab. 16. Residential home.ti.ab. 17. Residential facilities.ti.ab.
Design	<ol style="list-style-type: none"> 18. Randomised.ti.ab. 19. Randomized.ti.ab. 20. Controlled trials.ti.ab 21. RCT.ti.ab
	<ol style="list-style-type: none"> 22. OR/1-11 23. OR/12-17 24. OR/18-21 25. AND/22-24

